PPARs in Health and Disease, 2nd Edition

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 61

Special Issue Editor

E-Mail Website
Guest Editor
Department of Pharmacology, Faculty of Medicine, University of Ioannina, Ioannina 45110, Greece
Interests: drug metabolism; PPARα; stress systems biology; neural plasticity; antipsychotics in cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Peroxisome proliferator-activated receptors (PPARs) belong to a nuclear receptor superfamily, acting as ligand-activated transcription factors that exert specific pleiotropic responses. The three known isoforms, PPARα, PPARβ/δ, and PPARγ, have, among other things, determinant roles in energy homeostasis, regulating glucose and lipid metabolism. Upon binding with hormones, lipids, or other ligands, PPARs act by forming heterodimers with retinoic X receptors and, in cooperation with co-repressors or co-activators, regulate several target genes. They are involved in the pathophysiology of metabolic disorders and are pharmaceutical targets for their treatment. Specifically, PPARα and PPARγ agonists are used in the treatment of hyperlipidemia and type 2 diabetes, respectively. It also appears that the activation of PPARs affects carcinogenesis because it can be involved in the complex regulation of cancer cell type-specific proliferation, differentiation, and survival. In the last decade, intensive research has focused on the potential role of PPARα, PPARγ, and PPARβ/δ specific agonists in improving brain cell metabolism and cognitive function in neurodegenerative and neurodevelopmental disorders. PPARs also regulate morphogenesis and the inflammatory response. This Special Issue of Biomedicines includes the most recent advances in the regulation and function of PPARs and provides well-grounded views on therapeutic perspectives for the use of PPAR agonists or antagonists in various disease states, including dyslipidemia, atherosclerosis, obesity, diabetes, neurodegenerative disorders, and cancer.

Prof. Dr. Maria Konstandi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • PPARα
  • PPARβ/δ
  • PPARγ
  • nuclear receptor
  • lipid homeostasis
  • glucose homeostasis
  • neurodegenerative disorders
  • dyslipidemia
  • atherosclerosis
  • cardiovascular disease
  • cancer

Published Papers

This special issue is now open for submission.
Back to TopTop